179 related articles for article (PubMed ID: 24327695)
21. Moving toward targeted therapies in acute myeloid leukemia.
Gao W; Estey E
Clin Adv Hematol Oncol; 2015 Nov; 13(11):748-54. PubMed ID: 27058701
[TBL] [Abstract][Full Text] [Related]
22. Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia.
Ojamies PN; Kontro M; Edgren H; Ellonen P; Lagström S; Almusa H; Miettinen T; Eldfors S; Tamborero D; Wennerberg K; Heckman C; Porkka K; Wolf M; Kallioniemi O
Leukemia; 2017 May; 31(5):1048-1058. PubMed ID: 27795554
[TBL] [Abstract][Full Text] [Related]
23. Drug resistance in mutant FLT3-positive AML.
Weisberg E; Sattler M; Ray A; Griffin JD
Oncogene; 2010 Sep; 29(37):5120-34. PubMed ID: 20622902
[TBL] [Abstract][Full Text] [Related]
24. Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy.
Foran JM
Hematology; 2012 Apr; 17 Suppl 1():S137-40. PubMed ID: 22507802
[TBL] [Abstract][Full Text] [Related]
25. Small molecule inhibitors for acute myeloid leukemia: where is the field heading?
Trippier PC
Future Med Chem; 2017 Sep; 9(13):1453-1456. PubMed ID: 28795593
[No Abstract] [Full Text] [Related]
26. Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide.
Turk S; Turk C; Akbar MW; Kucukkaraduman B; Isbilen M; Demirkol Canli S; Malkan UY; Okay M; Ucar G; Sayinalp N; Haznedaroglu IC; Gure AO
PLoS One; 2020; 15(11):e0242497. PubMed ID: 33237942
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia.
Al-Riyami AZ; Hudoba M; Young S; Forrest D
Leuk Lymphoma; 2013 Aug; 54(8):1788-90. PubMed ID: 23157309
[No Abstract] [Full Text] [Related]
28. [Molecular targeting therapy by anti-VLA-4 monoclonal antibodies for AML].
Niitsu Y; Matsunaga T
Rinsho Ketsueki; 2005 Mar; 46(3):198-201. PubMed ID: 16447714
[No Abstract] [Full Text] [Related]
29. INFERENCE OF PERSONALIZED DRUG TARGETS VIA NETWORK PROPAGATION.
Shnaps O; Perry E; Silverbush D; Sharan R
Pac Symp Biocomput; 2016; 21():156-67. PubMed ID: 26776182
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine.
Bennett TA; Montesinos P; Moscardo F; Martinez-Cuadron D; Martinez J; Sierra J; García R; de Oteyza JP; Fernandez P; Serrano J; Fernandez A; Herrera P; Gonzalez A; Bethancourt C; Rodriguez-Macias G; Alonso A; Vera JA; Navas B; Lavilla E; Lopez JA; Jimenez S; Simiele A; Vidriales B; Gonzalez BJ; Burgaleta C; Hernandez Rivas JA; Mascuñano RC; Bautista G; Perez Simon JA; Fuente Ade L; Rayón C; Troconiz IF; Janda A; Bosanquet AG; Hernandez-Campo P; Primo D; Lopez R; Liebana B; Rojas JL; Gorrochategui J; Sanz MA; Ballesteros J
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):305-18. PubMed ID: 24468131
[TBL] [Abstract][Full Text] [Related]
31. Therapeutically Targetable ALK Mutations in Leukemia.
Maxson JE; Davare MA; Luty SB; Eide CA; Chang BH; Loriaux MM; Tognon CE; Bottomly D; Wilmot B; McWeeney SK; Druker BJ; Tyner JW
Cancer Res; 2015 Jun; 75(11):2146-50. PubMed ID: 26032424
[TBL] [Abstract][Full Text] [Related]
32. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
33. Explainable artificial intelligence for precision medicine in acute myeloid leukemia.
Gimeno M; San José-Enériz E; Villar S; Agirre X; Prosper F; Rubio A; Carazo F
Front Immunol; 2022; 13():977358. PubMed ID: 36248800
[TBL] [Abstract][Full Text] [Related]
34. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Wang F; Morita K; DiNardo CD; Furudate K; Tanaka T; Yan Y; Patel KP; MacBeth KJ; Wu B; Liu G; Frattini M; Matthews JA; Little LD; Gumbs C; Song X; Zhang J; Thompson EJ; Kadia TM; Garcia-Manero G; Jabbour E; Ravandi F; Bhalla KN; Konopleva M; Kantarjian HM; Andrew Futreal P; Takahashi K
Nat Commun; 2021 May; 12(1):2607. PubMed ID: 33972549
[TBL] [Abstract][Full Text] [Related]
35. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
36. Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia.
Gurnari C; Pagliuca S; Visconte V
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198085
[TBL] [Abstract][Full Text] [Related]
37. Expression of three different ATP-binding cassette transporters and correlation to chemoresistance in acute myeloid leukemia.
Palaiologou D; Panayiotidis P; Papanikolaou G; Georgiou G; Boutsikas G; Hatzinicolaou SL; Pangalis GA; Sakellaropoulos N; Vassilakopoulos TP; Angelopoulou MK
Int J Lab Hematol; 2015 Feb; 37(1):e7-e10. PubMed ID: 24809224
[No Abstract] [Full Text] [Related]
38. Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.
Miyamoto K; Minami Y
Int J Clin Oncol; 2019 Aug; 24(8):893-898. PubMed ID: 31111287
[TBL] [Abstract][Full Text] [Related]
39. Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?
Chung C; Ma H
Pharmacotherapy; 2017 Sep; 37(9):1052-1072. PubMed ID: 28654205
[TBL] [Abstract][Full Text] [Related]
40. Clinical Trials of Repurposing Medicines in Acute Myeloid Leukemia: Limitations and Possibilities in the Age of Precision Therapy.
Andresen V; Gjertsen BT
Cancer J; 2019; 25(2):153-163. PubMed ID: 30896540
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
